DaVita Inc.
Runs dialysis clinics for patients with kidney failure. Operates 3,200+ facilities, mostly in the US, treating ~300,000 patients per year. Revenue comes from per-treatment reimbursements paid by Medicare/Medicaid (~two-thirds of US revenue) and commercial insurers (~one-third). The business economics are heavily skewed: commercial insurance patients are only ~10% of the patient base but generate nearly all US dialysis profits, since Medicare reimbursement rates are much lower. Government policy around dialysis reimbursement is therefore a central business risk.
Employees78,000IPOAug 6, 2019SIC8092HQ2000 16th Street, Denver, CO, USA, 80202
to
Financials (MXN)
Profitability
Metric
Current
Margins
Gross Margin
32.4%
Operating Margin
14.9%
EBITDA Margin
19.8%
Net Margin
6.1%
OCF Margin
15.8%
FCF Margin
11.6%
Returns on Capital
ROE
—
ROA
4.8%
ROIC
10.4%
ROCE
14.1%
ROC (Greenblatt)
37.0%
3Y ROIIC
−149.2%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
14.66
Forward P/E
13.20
P/E ex-NRI
13.97
Shiller P/E (CAPE)
22.42
Cash Flow Multiples
P/FCF
7.88
P/OCF
5.77
P/Owner Earnings
10.35
FCF Yield
14.08%
Enterprise Value Multiples
EV / EBIT
12.61
EV / Forward EBIT
11.31
EV / EBITDA
9.38
EV / Forward EBITDA
8.36
EV / Revenue
1.86
EV / Forward Revenue
1.68
Asset / Sales
P/S
0.89
P/B
—
P/Tangible Book
—
Growth-Adjusted
PEG
1.07
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
0.00%
Forward Dividend Yield
0.00%
3Y Dividend Growth
0.0%
Payout Ratio
0.00
5Y Yield on Cost
0.00%
Buybacks & Dilution
3Y Buyback Ratio
8.80%
Combined
Shareholder Yield
7.34%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
−17.52
Gross Debt / EBITDA
4.84
Cash / Debt
0.05
Equity / Assets
−0.04
Coverage
Interest Coverage
3.52
Short-Term Liquidity
Current Ratio
1.47
Quick Ratio
1.41
Cash Ratio
0.24
Composite Scores
Piotroski F-Score
6
Altman Z-Score
1.68
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
No dividend history found.
Date
Transcript
Type
2026-08-04
Q2 2026 DaVita Inc Earnings Call Transcript
Earnings Call
2026-05-05
Q1 2026 DaVita Inc Earnings Call Transcript
Earnings Call
2026-03-02
DaVita Inc at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-02-02
Q4 2025 DaVita Inc Earnings Call Transcript
Earnings Call
2025-10-29
Q3 2025 DaVita Inc Earnings Call Transcript
Earnings Call
2025-08-05
Q2 2025 DaVita Inc Earnings Call Transcript
Earnings Call
2025-05-12
Q1 2025 DaVita Inc Earnings Call Transcript
Earnings Call
2025-02-13
Q4 2024 DaVita Inc Earnings Call Transcript
Earnings Call
2024-10-29
Q3 2024 DaVita Inc Earnings Call Transcript
Earnings Call
2024-08-06
Q2 2024 DaVita Inc Earnings Call Transcript
Earnings Call
10 of 40
5-Step DuPont Analysis
ROE %
-147.75%
×
×
Net Margin %
6.03%
×
×
Operating Margin %
14.92%
Operating Income
MX$37.46B
÷
Revenue
MX$251.03B
×
Tax Burden
0.5765
Net Income
MX$15.13B
÷
Pretax Income
MX$26.24B
×
Interest Burden
0.7005
Pretax Income
MX$26.24B
÷
Operating Income
MX$37.46B
×
Asset Turnover
0.78
÷
Revenue
MX$251.03B
÷
Average Total Assets
MX$323.83B
Begin Total Assets
MX$340.00B
End Total Assets
MX$307.66B
×
Equity Multiplier
-31.63
÷
Avg Total Assets
MX$323.83B
÷
Avg Stockholders Equity
−MX$10.24B
Begin Equity
−MX$7.18B
End Equity
−MX$13.29B